Overview Technical Risk & rank Quality Results Accounts Filings Options Guidance & governance
Guidance tracker
What SYNGENE guided, and what came next
| Filed | What the filing says | Next results: profit YoY | Revenue | Move on the day |
|---|---|---|---|---|
| 29 Jul 2026 | Syngene filed its Q1 FY27 investor presentation (quarter ended June 30, 2026) under Regulation 30 of SEBI LODR. Revenue from operations was Rs 736 Cr, down 16% Y-o-Y; operating EBITDA margin was 12% versus 24% in Q1 FY26. PAT before exceptional items was Rs 1 Cr; PAT after exceptional items was Rs -9 Cr, after Rs... NSE copy | -52.0 % | -8.6 % | +12.2 % |
| 29 Apr 2026 | Syngene International's board approved audited standalone and consolidated results for the quarter and year ended March 31, 2026. Consolidated revenue from operations for Q4 FY26 was Rs. 10,365 million; consolidated profit for the period was Rs. 1,479 million, against Rs. 1,833 million a year earlier. Consolidated... NSE copy | -110.4 % | -15.8 % | -3.6 % |
| 09 Sep 2025 | Syngene International filed an investor presentation dated September 9, 2025, for a Unit-3 plant visit and Q&A meeting with investors and analysts held the same day. The Unit-3 biologics facility was acquired from Stelis Biopharma in December 2023 for Rs 617 crores (USD 75 million), funded through internal accruals... NSE copy | -36.8 % | +2.2 % | -4.0 % |
| 12 Mar 2025 | Syngene International filed an investor presentation shared with investors and analysts at its investor meet held on March 12, 2025, referencing an earlier intimation dated March 7, 2025. The presentation shows revenue from operations rising from INR 14,231 mn in FY18 to INR 34,886 mn in FY21 and INR 50,239 mn in... NSE copy | +14.5 % | +10.7 % | -1.6 % |
Filings tagged as guidance, newest first (4 in all), with the company's next results after each: profit and revenue against the same quarter a year before, and the share's move on the results day. Whether the guidance was met is for the reader to judge from both; the site does not score it. The summaries are written by an AI model from the filing and can be wrong - the filing is the source.
Governance
Management, auditors, ratings and legal matters
| Filed | Kind | What the filing says |
|---|---|---|
| 29 Jul 2026 | Management change | Syngene filed its Q1 FY27 investor presentation (quarter ended June 30, 2026) under Regulation 30 of SEBI LODR. Revenue from operations was Rs 736 Cr, down 16% Y-o-Y; operating EBITDA margin was 12% versus 24% in Q1 FY26. PAT before exceptional items was Rs 1 Cr; PAT after exceptional items was Rs -9 Cr, after Rs... NSE copy |
| 30 Apr 2026 | Management change | Investor presentation for the quarter and year ended March 31, 2026, filed under Regulation 30, to be used for meetings with analysts and institutional investors. Q4 FY26 revenue from operations was Rs 1,037 Cr (2% Y-o-Y, about USD 112 Mn), with operating EBITDA margin of 29% (34% in Q4 FY25) and PAT before... NSE copy |
| 29 Apr 2026 | Management change | Board of Syngene International approved audited standalone and consolidated results for the quarter and year ended March 31, 2026. Standalone FY2026 revenue from operations was Rs. 34,238 million and profit for the year was Rs. 3,049 million; Q4 FY2026 standalone profit was Rs. 1,482 million. Consolidated FY2026... NSE copy |
| 29 Apr 2026 | Management change | Syngene International's board approved audited standalone and consolidated results for the quarter and year ended March 31, 2026. Consolidated revenue from operations for Q4 FY26 was Rs. 10,365 million; consolidated profit for the period was Rs. 1,479 million, against Rs. 1,833 million a year earlier. Consolidated... NSE copy |
| 22 Jan 2026 | Legal or regulatory | Syngene International Limited's board approved the unaudited standalone and consolidated Ind AS financial results for the quarter and nine months ended December 31, 2025 at its meeting held on January 22, 2026. Standalone revenue from operations was Rs. 8,344 million for the quarter ended December 31, 2025 (Rs.... NSE copy |
| 06 Nov 2025 | Legal or regulatory | Syngene International filed its investor presentation for the quarter and half year ended September 30, 2025 (Q2 FY26 and H1 FY26), to be used for meetings with analysts or institutional investors. Q2 FY26 revenue from operations was Rs 911 Cr (2% Y-o-Y, about USD 103 Mn), with operating EBITDA margin of 22% (27%... NSE copy |
| 09 Sep 2025 | Legal or regulatory | Syngene International filed an investor presentation dated September 9, 2025, for a Unit-3 plant visit and Q&A meeting with investors and analysts held the same day. The Unit-3 biologics facility was acquired from Stelis Biopharma in December 2023 for Rs 617 crores (USD 75 million), funded through internal accruals... NSE copy |
| 24 Jul 2025 | Legal or regulatory | Syngene International filed its investor presentation for the quarter ended June 30, 2025 (Q1 FY26) under Regulation 30, to be used for meetings with analysts or institutional investors. Q1 FY26 revenue from operations was Rs 875 Cr, up 11% year-on-year (about USD 102 Mn at about INR 86 per USD). Operating EBITDA... NSE copy |
| 24 Apr 2025 | Legal or regulatory, Management change | Board of Syngene International approved audited standalone and consolidated Ind-AS results for the quarter and year ended March 31, 2025, filed with the exchanges on April 23, 2025. Standalone revenue from operations for FY2025 was Rs. 33,733 million versus Rs. 32,031 million in FY2024; consolidated revenue from... NSE copy |
| 23 Apr 2025 | Legal or regulatory, Management change | Board of Syngene International approved audited standalone and consolidated Ind-AS financial results for the quarter and year ended March 31, 2025. Board recommended a final dividend of Re.1.25 per equity share of Rs.10 for FY 2024-25, with record date Friday, June 27, 2025. Board approved appointment of V... NSE copy |
Filings with a management change, a legal or regulatory matter or a credit rating (by their tags), or naming an auditor, a resignation or a pledge of shares; newest first (10 in all). A list of what was filed, not a judgement of the company.